The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study

BMC Infectious Diseases

Table 4 The relationship of IRIS occurrence and initiation timing of HAART among HIV-TB co-infected patients*

	Total (n = 182)	IRIS (N = 57, 25%)	Hazard ratio (95% CI)	Adjusted HR^#(95% CI)	Adjusted HR^$(95% CI)
Age at TB diagnosis (per 5-year increase)			0.99 (0.97-1.01)	0.99 (0.97-1.02)	0.99 (0.97-1.02)
CD4 count at TB diagnosis (per 50-cell increase)			0.95 (0.81-1.11)	0.97 (0.83-1.13)	0.97 (0.83-1.13)
HAART initiation timing during anti-TB therapy
0–15 days	110	41 (71.9%)	1	1	4.24 (1.02-19.5)
16–30 days	34	12 (21.1%)	0.98 (0.51-1.86)	0.96 (0.50-1.84)	4.08 (0.91-18.3)
31–60 days	19	2 (3.5%)	0.23 (0.06-0.96)	0.24 (0.06-0.98)	1
>60 days	19	2 (3.5%)	0.26 (0.06-1.06)	0.27 (0.07-1.12)	1.14 (0.16-8.11)

Abbreviations: HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
*Only enrolled cases with available CD4+ lymphocyte count and start HAART during TB treatment. HBV co-infection, HCV co-infection and TB location were analyzed initially but the p-value was greater than 0.15 and was not included for multivariate analysis and not shown in the table.
#Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 0–15 days as reference).
^$Adjusted for age at TB diagnosis, CD4+ lymphocyte count and HAART initiation timing (use initiation timing at 31–60 days as reference).

ISSN: 1471-2334